TC-D101 CAR-T

Phase 1Cell therapy

TTCRCure Biopharma Ltd.

TC-D101 CAR-T is one of 9 biologic programs targeting Cell Therapy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cell TherapyRecruiting

Cell TherapyPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Cell Therapy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

5 2

Keytruda

Merck & Co.

Phase 2

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

5 4

Anti-CD19 CAR NK Cells

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

1 5

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

1 6

Lymphodepletion Chemotherapy

MMarcela V. Maus, M.D.,Ph.D.

Phase 2

1 7

TC-D101 CAR-T

TTCRCure Biopharma Ltd.

Phase 1

1 8

Cellular Therapy

Sanofi

Preclinical

1 9

ECT204 T Cells

EEureka Therapeutics Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Cell Therapy

NCT07246304

Clinical

Trials by Indication[1]

Cell Therapy1 trial

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Recruiting·TTCRCure Biopharma Ltd.·Phase 1·NCT07246304·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TC-D101 CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TC-D101 CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TC-D101 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TCRCure Biopharma Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TTCRCure Biopharma Ltd.

TC-D101 CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News